Emmaus CEO and Chairman steps down; interim Co-Presidents appointed

Emmaus Life Sciences, Inc.

Yutaka Niihara, M.D., Ph.D., leaves CEO and Chairman roles effective Aug 18, 2023, to pursue other projects; remains a director.
Willis Lee (COO) and George Sekulich (CIO) appointed interim Co-Presidents pending CEO search.
George Sekulich's base salary set at $210,000; eligible for stock plan awards.
Company to focus on Endari sales in U.S. and MENA, expects generic competition in 2024.
Discontinuing non-Endari activities to reduce operating costs and improve cash flow.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Willis Lee

interim Co-President

EMMA · Emmaus Life Sciences, Inc.

Filed: August 23, 2023, 7:59 PM ET

Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.

Appointed (interim)

George Sekulich

interim Co-President

EMMA · Emmaus Life Sciences, Inc.

Filed: August 23, 2023, 7:59 PM ET

Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Willis Lee was appointed as interim Co-President at Emmaus Life Sciences, Inc..

Action: appointed
Role: interim Co-President

Exact text from the filing

Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

George Sekulich was appointed as interim Co-President at Emmaus Life Sciences, Inc..

Action: appointed
Role: interim Co-President

Exact text from the filing

Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.

View on SEC.gov

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-070110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.